In our study, we demonstrate for the first time that lower baseline serum IL-18 levels in patients with psoriasis may predict an excellent clinical response to biologic therapy with secukinumab, defined as complete skin clearance (PASI = 0) at three months. This evidence concerns the gene IL18 and psoriasis.